158 related articles for article (PubMed ID: 37690811)
41. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
[TBL] [Abstract][Full Text] [Related]
42. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
[TBL] [Abstract][Full Text] [Related]
43. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
44. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
45. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
46. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
[TBL] [Abstract][Full Text] [Related]
47. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
[TBL] [Abstract][Full Text] [Related]
48. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.
Perrone S; Lopedote P; Levis M; Di Rocco A; Smith SD
Expert Rev Hematol; 2022 Mar; 15(3):215-232. PubMed ID: 35184664
[TBL] [Abstract][Full Text] [Related]
49. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
50. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
51. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Perales MA; Anderson LD; Jain T; Kenderian SS; Oluwole OO; Shah GL; Svoboda J; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):546-559. PubMed ID: 35768052
[TBL] [Abstract][Full Text] [Related]
52. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
53. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
54. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
Front Immunol; 2022; 13():873789. PubMed ID: 35572515
[TBL] [Abstract][Full Text] [Related]
55. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ; Leick MB; Maurer K; Gohil SH; Larson RC; Yao N; Gallagher KME; Katsis K; Frigault MJ; Southard J; Li S; Kann MC; Silva H; Jan M; Rhrissorrakrai K; Utro F; Levovitz C; Jacobs RA; Slowik K; Danysh BP; Livak KJ; Parida L; Ferry J; Jacobson C; Wu CJ; Getz G; Maus MV
Nat Med; 2022 Sep; 28(9):1848-1859. PubMed ID: 36097221
[TBL] [Abstract][Full Text] [Related]
56. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
57. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
59. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
Locke FL; Go WY; Neelapu SS
JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
[TBL] [Abstract][Full Text] [Related]
60. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ; Kurtz DM; Alig SK; Frank MJ; Shukla N; Garofalo A; Macaulay CW; Shahrokh Esfahani M; Olsen MN; Hamilton J; Hosoya H; Hamilton M; Spiegel JY; Baird JH; Sugio T; Carleton M; Craig AFM; Younes SF; Sahaf B; Sheybani ND; Schroers-Martin JG; Liu CL; Oak JS; Jin MC; Beygi S; Hüttmann A; Hanoun C; Dührsen U; Westin JR; Khodadoust MS; Natkunam Y; Majzner RG; Mackall CL; Diehn M; Miklos DB; Alizadeh AA
Cancer Cell; 2023 Jan; 41(1):210-225.e5. PubMed ID: 36584673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]